)
Edge15 May 2026
TOMRA: Closing the Loop
The story of TOMRA: from reverse vending machine pioneer to global technology for deposit systems, recycling, and resource optimization.
GH Research
GH Research (GHRS) investor relations material
GH Research Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration filing summary14 May, 2026
Company overview and business model
Clinical-stage biopharmaceutical company focused on developing novel mebufotenin therapies for treatment-resistant depression (TRD), with lead candidates GH001 (inhalable) and GH002 (intravenous).
GH001 has completed multiple Phase 1 and Phase 2 trials, showing potential for ultra-rapid remission in TRD patients.
Developing a proprietary aerosol delivery device for GH001, currently under clinical investigation in Europe.
Incorporated in Ireland, operates as a holding company for GH Research Ireland Limited.
Financial performance and metrics
As of March 31, 2026, 62,052,506 ordinary shares were outstanding; as of May 12, 2026, 68,608,919 shares were outstanding.
Share capital changes since January 1, 2023, include significant underwritten offerings and option exercises.
Use of proceeds and capital allocation
Net proceeds from offerings intended for research, clinical and technical development, pre-commercialization activities, working capital, capital expenditures, and general corporate purposes.
Management retains significant discretion over allocation of proceeds.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from GH Research
- GH001 achieved rapid, durable remission in TRD with minimal visits and strong safety.GHRS
Corporate presentation5 Mar 2026 - GH001 showed robust Phase 2b results in TRD; cash rose to $280.7M, net loss at $48.3M.GHRSQ4 20255 Mar 2026
- GH001 delivers rapid, durable remission in TRD with strong safety and fewer clinic visits.GHRSStatus Update9 Jan 2026
- Up to $400M in securities registered to fund novel depression therapies and corporate growth.GHRSRegistration Filing16 Dec 2025
- GH001 achieved significant efficacy in TRD; cash reserves rose to $293.9M; Q3 net loss $14M.GHRSQ3 202520 Nov 2025
- Pivotal depression program on track for 2026, with strong cash and robust Phase 2b results.GHRSQ2 202512 Sep 2025
- Phase 2b GH001 trial enrollment completed; net loss rises as R&D spending increases.GHRSQ3 202413 Jun 2025
- Q2 net loss widened to $10.4M as GH001 clinical programs advanced and cash runway extends into 2026.GHRSQ2 202413 Jun 2025
- Q1 2025 saw strong GH001 trial results, robust cash, and progress on regulatory milestones.GHRSQ1 20259 Jun 2025
Next GH Research earnings date
Q1 202628 May, 2026
GH Research
Next GH Research earnings date
Q1 202628 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage